// App-Quantinova.ai

1397 : Natural Killer Cells In Pediatric Acute Lymphoblastic Leukemia Patients At Diagnosis Demonstrate An Inhibitory Phenotype and Reduced Cytolytic Capacity

Researchers

Presenter

  • Rayne H. Rouce

Principal Investigators

  • Takuya Sekine

  • Gerrit Weber

  • Claude Chew

  • Katayoun Rezvani

  • Catherine M. Bollard

  • Karen R Rabin

Medical Centers

  • Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Childrens Hospital, Houston Methodist Hospital, Houston, TX

  • Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute for Pediatric Surgical Innovation, and Center for Cancer and Immunology Research, Childrens National Health System, Washington, DC

  • Stem Cell Transplantation, MD Anderson Cancer Center, Houston,

  • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX

  • Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Mismatch repair deficiency

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Natural Killer cells

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 107 Antigen-Like Family Member A

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 56

  • Tumor necrosis factor

  • Natural killer group 2D

  • NKp46

Drug/Treatment

  • lonomycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved